Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
Open Access
- 12 July 2009
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 146 (3), 282-291
- https://doi.org/10.1111/j.1365-2141.2009.07773.x
Abstract
Toll‐like receptor‐9 (TLR‐9) agonists have pleotropic effects on both the innate and adaptive immune systems, including increased antigen expression, enhanced antibody‐dependent cell‐mediated cytotoxicity (ADCC) and T helper cell type 1 shift in the immune response. We combined a TLR‐9 agonist (1018 ISS, 0·2 mg/kg sc weekly × 4 beginning day 8) with standard rituximab (375 mg/m2 weekly × 4) in patients (n = 23) with relapsed/refractory, histologically confirmed follicular lymphoma, and evaluated immunological changes following the combination. Treatment was well‐tolerated with no significant adverse events attributable to therapy. Clinical responses were observed in 48% of patients; the overall median progression‐free survival was 9 months. Biologically relevant increases in ADCC and circulating CD‐3 positive T cells were observed in 35% and 39% of patients, respectively. Forty‐five percent of patients had increased T cells and dendritic cells in skin biopsies of 1018 ISS injection sites 24 h post‐therapy. Pre‐ and post‐biopsies of tumour tissue demonstrated an infiltration of CD8+ T cells and macrophages following treatment. This group of patients had favourable clinical outcome despite adverse prognostic factors. This study is the first to histologically confirm perturbation of the local immune microenvironment following systemic biological therapy of follicular lymphoma.Keywords
This publication has 41 references indexed in Scilit:
- NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphomaExperimental Hematology, 2008
- Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's LymphomaClinical Cancer Research, 2007
- Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor ItselfThe Journal of Immunology, 2007
- B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogenyClinical Immunology, 2007
- CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular LymphomaClinical Cancer Research, 2007
- CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cellsInternational Immunopharmacology, 2006
- Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma PatientsJournal of Clinical Oncology, 2006
- In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotidesBlood, 2006
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin LymphomaJournal of Immunotherapy, 2006
- Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphomaCurrent Treatment Options in Oncology, 2006